A national coverage determination (NCD) related to implanted cardioverter defibrillators (ICD) is causing some confusion. The NCD was issued on February 15, and the changes, while billed as “relatively minimal,” may actually require significant process alterations.
Q: We are having trouble determining what qualifies a patient as having an acute myocardial infarction (MI) and what documentation would support the diagnosis. Can you help our coding team clarify?
Q. I’ve been taught to tell our patients, “We look forward to seeing you on x day at x time with x doctor.” This has always been left on cell phone voice mails or home phones. Is this a HIPAA-compliant practice?
This week's note from the instructor highlights billing and coding regulations for specimen validity tests billed in combination with urine drug tests in the wake of an OIG audit which found a 99% error rate for these claims.
CMS reminded organizations to pay attention to billing and coding for specimen validity testing done in conjunction with drug testing. The agency reviewed recent code changes and billing guidelines for these lab tests in Special Edition MLN Matters 18001 released on March 29. CMS emphasized that providers that perform validity testing on urine specimens cannot separately bill the validity testing.
Amidst the hospital-of-the-future buzz at HIMSS18 was keen interest in resources aimed at helping providers navigate the present-day transition to value-based care. Many healthcare executive and clinician attendees were eager to identify ways healthcare technology can help their organizations transition from fee-for-service to pay-for-performance reimbursement models.
